The 21st CPHI China 2023 and the 16th PMEC China 2023 were successfully concluded on June 19-21, 2023 in Shanghai. CPHI China 2023 has successfully concluded in Shanghai from June 19-21, 2023! CPHI China 2023 has built a high-quality trade platform for the exchange, cooperation and co-prosperity of the global pharmaceutical industry, and the number of exhibitors and visitors reached a new record high in 2023, with a luxurious lineup of nearly 3,400 exhibitors converging on the city of Shenyang to showcase their innovative products, cutting-edge technologies and prospective solutions; professional buyers from 120+ countries and regions attended the event, and visitors from more than 100 countries and regions participated in the event. Professional buyers from 120+ countries and regions joined the event, and the total number of visitors increased by more than 30% compared with 2019. The exhibition site is crowded, and the business boom has started again.
Chinese Peptide company was invited to participate in the 2nd Peptide Drug Industry Innovation Forum, and there was a strong atmosphere of academic exchange, during which Chinese Peptide company exhibitors had a lively discussion with all the guests and industry colleagues, and introduced the latest research progress in the leading fields of peptide and nucleic acid CRDMO services.
Founded in 2001, Chinese peptide company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.
The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.